SEARCH

SEARCH BY CITATION

References

  • 1
    Spiro SG, Porter JC. Lung cancer—where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002; 166: 116696.
  • 2
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 3
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 928.
  • 4
    Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 31723.
  • 5
    Argiris A, Murren JR. Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents. Cancer J 2001; 7: 22835.
  • 6
    Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003; 21: 2917.
  • 7
    Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 141318.
  • 8
    Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003; 88: 33541.
  • 9
    Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 218294.
  • 10
    Rothenberg ML, Kuhn JG, Burris HA, III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Holf DD. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194204.
  • 11
    Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28: 42333.
  • 12
    Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95109.
  • 13
    Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6: 193210.
  • 14
    Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 638792.
  • 15
    Matsumura Y, Maruo K, Kimura M, Yamamoto T, Konno T, Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 1991; 82: 73241.
  • 16
    Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Kenmotsu H, Sugino T, Matsumura Y. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin Cancer Res 2010; 16: 5219.
  • 17
    Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006; 66: 1004856.
  • 18
    Nakajima TE, Yasunaga M, Kano Y, Koizumi F, Kato K, Hamaguchi T, Yamada Y, Shirao K, Shimada Y, Matsumura Y. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int J Cancer 2008; 122: 214853.
  • 19
    Sumitomo M, Koizumi F, Asano T, Horiguchi A, Ito K, Asano T, Kakizoe T, Hayakawa M, Matsumura Y. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res 2008; 68: 16315.
  • 20
    Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci 2008; 99: 125864.
  • 21
    Eguchi Nakajima T, Yanagihara K, Takigahira M, Yasunaga M, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Mihara K, Ochiya T, Matsumura Y. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res 2008; 68: 931822.
  • 22
    Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 2009; 124: 250511
  • 23
    Kato K, Hamaguchi T, Shirao K, Shimada Y, Doi T, Ohtsu A, Matsumura Y, Yamada Y. Interim analysis of phase I study of NK012, polymer micelle SN-38, in patients with advanced cancer. Proc Am Soc Clin Oncol 2008 (Abstract No. 485).
  • 24
    Burris HA, III, Infante JR, Spigel DR, Greco FA, Thompson DS, Matsumoto S, Kawamura S, Jones SF. A phase I dose-escalation study of NK012. Proc Am Soc Clin Oncol 2008 (Abstract No. 2538).
  • 25
    Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004; 10: 11219.
  • 26
    Takiuchi H, Kawabe S-i, Gotoh M, Katsu K-i. Thymidylate synthase gene expression in primary tumors predicts activity of S-1-based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res 2007; 1: 1716.
  • 27
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 13227.
  • 28
    Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 23716.
  • 29
    Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 96873.
  • 30
    Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 40049.
  • 31
    Muraoka A, Suehiro I, Fujii M, Nagata K, Kusunoki H, Kumon Y, Shirasaka D, Hosooka T, Murakami K. Acute gastric anisakiasis: 28 cases during the last 10 years. Dig Dis Sci 1996; 41: 23625.
  • 32
    Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 2755.
  • 33
    Kamiyama H, Takano S, Tsuboi K, Matsumura A. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 α (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 2005; 131: 20513.
  • 34
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 2008; 7: 599606.
  • 35
    Brun Y, Wang XP, Willemot J, Sevenet T, Demenge P. Experimental study of antidiarrheal activity of Salicairine. Fundam Clin Pharmacol 1998; 12: 306.
  • 36
    Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000; 60: 21906.
  • 37
    Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005; 93: 67887.
  • 38
    Okamoto I, Nishimura T, Miyazaki M, Yoshioka H, Kubo A, Takeda K, Ebi N, Sugawara S, Katakami N, Fukuoka M, Nakagawa K. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505. Clin Cancer Res 2008; 14: 52504.
  • 39
    Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006; 94: 11305.
  • 40
    Takechi T, Okabe H, Ikeda K, Fujioka A, Nakagawa F, Ohshimo H, Kitazato K, Fukushima M. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Rep 2005; 14: 339.
  • 41
    Ohe Y, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Kojima A, Kunikane H, Okamoto H, Karato A, Ohmatsu H, Kanzawa F, Saijo N. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992; 84: 9724.
  • 42
    Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 12259.
  • 43
    Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 190712.
  • 44
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 181020.
  • 45
    Nagano T, Yasunaga M, Goto K, Koga Y, Kuroda J-i, Nishimura Y, Sugino T, Nishiwaki Y, Matsumura Y. Antitumor activity of NK012 combined with cisplatin against small-cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. Clin Cancer Res 2009; 15: 434855.